Longitudinal utilization of systemic immunomodulators before and after dupilumab approval in children with atopic dermatitis

In our cohort study, we sought to describe the utilization patterns of systemic immunomodulators in children with atopic dermatitis (AD) and how utilization changed after approval of dupilumab, the first systemic drug approved for the treatment of AD. Using US nationwide claims data, we identified children with AD who initiated a systemic therapy (dupilumab, cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil) from March 2015 to February 2021 and used Sankey plots to describe patterns of starting, switching, and discontinuing these drugs. Dupilumab use among children increased from 19.4% before approval in children to 88.3% after approval in 2019-20. Adherence to dupilumab may suggest better tolerance and improved outcomes in children with AD.

Automated summary

This cohort study aimed to investigate the utilization patterns of systemic immunomodulators in children with atopic dermatitis (AD) and how the patterns changed after the approval of dupilumab. The results showed that the use of dupilumab significantly increased among children with AD after approval, suggesting improved tolerance and outcomes.